Kazia Therapeutics Annual Report 2021

Sponsor Phase Indication Registration Kazia Therapeutics II Glioblastoma NCT03522298 Global Coalition for Adaptive Research II / III Glioblastoma NCT03970447 Weill Cornell Cancer Center II Glioblastoma (with ketogenic diet) TBD Alliance for Clinical Trials in Oncology II Brain metastases NCT03994796 Dana-Farber Cancer Institute II Breast cancer brain metastases (with Herceptin) NCT03765983 Dana-Farber Cancer Institute II Primary CNS lymphoma NCT04906096 Pacific Pediatric Neuro-Oncology Consortium II DIPG & DMGs (childhood brain cancer) TBD St Jude Children’s Research Hospital I DIPG (childhood brain cancer) NCT03696355 Memorial Sloan Kettering Cancer Center I Brain metastases (with radiotherapy) NCT04192981 PIPELINE REVIEW: TWO FIRST-CLASS DEVELOPMENT CANDIDATES (continued) EVT801 In April 2021, Kazia licensed EVT801, an investigational new drug for multiple forms of cancer, from Evotec SE, a European drug development company. EVT801 is now Kazia’s second pipeline asset, behind paxalisib, and it represents a tremendously exciting addition to the company’s portfolio. An introduction to EVT801 can be found later in this Annual Report. In terms of activity, however, the entire focus of the program since April has been on launching a phase I clinical trial by the end of CY2021. The Kazia and Evotec teams have been working closely together to design a cutting-edge study protocol, identify suitable clinical trial sites, manufacture investigational product, and navigate the European regulatory processes. The study remains well on track, indeed potentially ahead of schedule. The transition into a human trial is always an enormous step in the development of any new medicine. For EVT801, we expect that the study will rapidly begin to generate data that demonstrates its potential, guides its future development, and establishes it as a worthy companion to paxalisib in the Kazia portfolio. Such a rapid transition into human trials is only possible with the benefit of a compelling package of preclinical data. Kazia and Evotec have begun work on an academic publication that will summarise this rich body of data, and it is expected that this will be published in a peer-reviewed academic journal and communicated to investors by the end of CY2021. Sponsor Phase Indication Registration Kazia Therapeutics I Advanced Solid Tumours TBD Kazia Therapeutics Limited 12 Annual Report 2021